Eugenia Ulzurrun

987 total citations
21 papers, 674 citations indexed

About

Eugenia Ulzurrun is a scholar working on Pharmacology, Molecular Biology and Oncology. According to data from OpenAlex, Eugenia Ulzurrun has authored 21 papers receiving a total of 674 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Pharmacology, 8 papers in Molecular Biology and 4 papers in Oncology. Recurrent topics in Eugenia Ulzurrun's work include Drug-Induced Hepatotoxicity and Protection (9 papers), Pharmacogenetics and Drug Metabolism (6 papers) and Drug Transport and Resistance Mechanisms (4 papers). Eugenia Ulzurrun is often cited by papers focused on Drug-Induced Hepatotoxicity and Protection (9 papers), Pharmacogenetics and Drug Metabolism (6 papers) and Drug Transport and Resistance Mechanisms (4 papers). Eugenia Ulzurrun collaborates with scholars based in Spain, United States and Chile. Eugenia Ulzurrun's co-authors include M. Isabel Lucena, Raúl J. Andrade, Manuel Romero‐Gómez, Mercedes Robles‐Díaz, Camilla Stephens, M. Carmen Fernández, Y. Borraz, José A. G. Agúndez, Elena Garcı́a-Martı́n and Ramón Planas and has published in prestigious journals such as Bioinformatics, Gastroenterology and PLoS ONE.

In The Last Decade

Eugenia Ulzurrun

17 papers receiving 657 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Eugenia Ulzurrun Spain 9 466 189 178 131 86 21 674
M. Carmen Fernández Spain 6 636 1.4× 230 1.2× 225 1.3× 166 1.3× 71 0.8× 7 793
A. González-Jiménez Spain 11 444 1.0× 117 0.6× 230 1.3× 160 1.2× 69 0.8× 37 721
Miguel Jiménez‐Pérez Spain 7 266 0.6× 75 0.4× 157 0.9× 105 0.8× 67 0.8× 7 432
Joanna I. Clarke United Kingdom 6 203 0.4× 114 0.6× 134 0.8× 132 1.0× 129 1.5× 9 482
Basuki Gunawan United States 6 605 1.3× 149 0.8× 243 1.4× 351 2.7× 188 2.2× 8 867
Naga P. Chalasani United States 5 225 0.5× 95 0.5× 367 2.1× 212 1.6× 54 0.6× 8 585
J. Terrence Coyle United Kingdom 8 427 0.9× 76 0.4× 120 0.7× 165 1.3× 104 1.2× 16 665
Gebran Abboud United States 4 258 0.6× 91 0.5× 86 0.5× 87 0.7× 48 0.6× 7 539
Brian C. Ferslew United States 10 133 0.3× 315 1.7× 311 1.7× 98 0.7× 160 1.9× 18 609
Luqi Duan United States 9 230 0.5× 52 0.3× 81 0.5× 122 0.9× 86 1.0× 14 404

Countries citing papers authored by Eugenia Ulzurrun

Since Specialization
Citations

This map shows the geographic impact of Eugenia Ulzurrun's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eugenia Ulzurrun with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eugenia Ulzurrun more than expected).

Fields of papers citing papers by Eugenia Ulzurrun

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eugenia Ulzurrun. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eugenia Ulzurrun. The network helps show where Eugenia Ulzurrun may publish in the future.

Co-authorship network of co-authors of Eugenia Ulzurrun

This figure shows the co-authorship network connecting the top 25 collaborators of Eugenia Ulzurrun. A scholar is included among the top collaborators of Eugenia Ulzurrun based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eugenia Ulzurrun. Eugenia Ulzurrun is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ulzurrun, Eugenia, Eulalia Rodrı́guez-Martı́n, Javier García‐Nafría, et al.. (2025). FDA Drug Repurposing Uncovers Modulators of Dopamine D 2 Receptor Localization via Disruption of the NCS-1 Interaction. Journal of Medicinal Chemistry. 68(22). 23993–24010.
2.
Ulzurrun, Eugenia, et al.. (2025). AI-Driven De Novo Design and Development of Nontoxic DYRK1A Inhibitors. Journal of Medicinal Chemistry. 68(10). 10346–10364. 1 indexed citations
3.
4.
Ulzurrun, Eugenia, et al.. (2023). Scipion-Chem: An Open Platform for Virtual Drug Screening. Journal of Chemical Information and Modeling. 63(24). 7873–7885. 1 indexed citations
5.
Margolin, William, Eugenia Ulzurrun, Carlo Zanotto, et al.. (2023). Benzodioxane–Benzamides as FtsZ Inhibitors: Effects of Linker’s Functionalization on Gram-Positive Antimicrobial Activity. Antibiotics. 12(12). 1712–1712. 3 indexed citations
6.
Pérez, Concepción, Adrián Gironda-Martínez, Eugenia Ulzurrun, et al.. (2022). Multitarget drugs as potential therapeutic agents for alzheimer’s disease. A new family of 5-substituted indazole derivatives as cholinergic and BACE1 inhibitors. Journal of Enzyme Inhibition and Medicinal Chemistry. 37(1). 2348–2356. 7 indexed citations
7.
Ulzurrun, Eugenia, et al.. (2020). PLIDflow: an open-source workflow for the online analysis of protein–ligand docking using galaxy. Bioinformatics. 36(14). 4203–4205. 2 indexed citations
8.
Arjona-Medina, Jose A., et al.. (2016). Computational workflow for the fine-grained analysis of metagenomic samples. BMC Genomics. 17(S8). 802–802. 4 indexed citations
9.
Robles‐Díaz, Mercedes, M. Isabel Lucena, Neil Kaplowitz, et al.. (2014). Use of Hy's Law and a New Composite Algorithm to Predict Acute Liver Failure in Patients With Drug-Induced Liver Injury. Gastroenterology. 147(1). 109–118.e5. 223 indexed citations
10.
Ulzurrun, Eugenia, Camilla Stephens, Francisco Ruiz‐Cabello, et al.. (2014). Selected ABCB1, ABCB4 and ABCC2 Polymorphisms Do Not Enhance the Risk of Drug-Induced Hepatotoxicity in a Spanish Cohort. PLoS ONE. 9(4). e94675–e94675. 14 indexed citations
11.
Stephens, Camilla, Miguel Ángel López‐Nevot, Francisco Ruiz‐Cabello, et al.. (2013). HLA Alleles Influence the Clinical Signature of Amoxicillin-Clavulanate Hepatotoxicity. PLoS ONE. 8(7). e68111–e68111. 71 indexed citations
12.
Ulzurrun, Eugenia, Camilla Stephens, Francisco Ruiz‐Cabello, et al.. (2013). Role of chemical structures and the 1331T>C bile salt export pump polymorphism in idiosyncratic drug‐induced liver injury. Liver International. 33(9). 1378–1385. 34 indexed citations
13.
Lucena, M. Isabel, Henry Cohen, Nelia Hernández, et al.. (2011). Hepatotoxicidad, un problema global con especificidades locales: hacia la creación de una Red Hispano Latinoamericana de Hepatotoxicidad. Gastroenterología y Hepatología. 34(5). 361–368. 8 indexed citations
14.
Lucena, M. Isabel, Elena Garcı́a-Martı́n, Raúl J. Andrade, et al.. (2010). Mitochondrial Superoxide Dismutase and Glutathione Peroxidase in Idiosyncratic Drug-Induced Liver Injury. Hepatology. 52(1). 303–312. 75 indexed citations
15.
Andrade, Raúl J., Mercedes Robles‐Díaz, Eugenia Ulzurrun, & M. Isabel Lucena. (2009). Drug-Induced Liver Injury: Insights from Genetic Studies. Pharmacogenomics. 10(9). 1467–1487. 70 indexed citations
16.
Lucena, M. Isabel, Carmen Martı́nez, Raúl J. Andrade, et al.. (2009). Glutathione S-transferase M1 and T1 null genotypes increase susceptibility to drug-induced liver injury # † ‡. Hepatology. 49(5). 1777–1779.
17.
Valdivielso, Pedro, et al.. (2008). Association of the -250G/A promoter polymorphism of the hepatic lipase gene with the risk of peripheral arterial disease in type 2 diabetic patients. Journal of Diabetes and its Complications. 22(4). 273–277. 15 indexed citations
18.
Lucena, M. Isabel, Raúl J. Andrade, Carmen Martínez, et al.. (2008). Glutathione S‐transferase m1 and t1 null genotypes increase susceptibility to idiosyncratic drug‐induced liver injury†. Hepatology. 48(2). 588–596. 138 indexed citations
19.
Rioja, José, et al.. (2007). 5-HT1A receptor activation counteracted the effect of acute immobilization of noradrenergic neurons in the rat locus coeruleus. Neuroscience Letters. 412(1). 84–88. 6 indexed citations
20.
Rioja, José, et al.. (2006). We-P11:5 Postprandial lipemia and insulin resistance in individuals with and without type 2 diabetes. Atherosclerosis Supplements. 7(3). 347–347. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by M. Carmen Fernández Breakdown of academic impact, for papers by A. González-Jiménez Breakdown of academic impact, for papers by Miguel Jiménez‐Pérez Breakdown of academic impact, for papers by Joanna I. Clarke Breakdown of academic impact, for papers by Basuki Gunawan Breakdown of academic impact, for papers by Naga P. Chalasani Breakdown of academic impact, for papers by J. Terrence Coyle Breakdown of academic impact, for papers by Gebran Abboud Breakdown of academic impact, for papers by Brian C. Ferslew Breakdown of academic impact, for papers by Luqi Duan
Rankless by CCL
2026